ESMO 2020: PARP inhibitor olaparib for the targeted treatment of metastatic prostate cancer - ecancer
PDF) Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Expanding the Therapeutic Opportunities in Advanced Prostate Cancer | ESMO
Olaparib Outperforms Enzalutamide or Abiraterone Acetate
Sequencing Life-Prolonging Agents in Prostate Cancer | ESMO
Actionable Targets In Advanced Prostate Cancer: The Potential of Molecular Profiling and Radioligand Therapy | ESMO
Prostate Cancer Highlights from ESMO 2022 - YouTube
Prostate Cancer Highlights from ESMO 2022 - YouTube
Mapping Pathways for PARP Inhibition in Prostate Cancer: Practical Considerations for Clinical Practice | ESMO
Women Against Prostate Cancer: Optimal Use of Chemotherapy in Metastatic Prostate Cancer | ESMO
ESMO Virtual Preceptorship on Prostate Cancer 2020
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology
ESMO 2019: Invited Discussant: The CARD Trial – Cabazitaxel as Third Line Therapy in Metastatic Castration-Resistant Prostate Cancer – Philippine Endourological Society
Updated Therapeutic Approach of Castration-Resistant Prostate Cancer (CRPC) | ESMO
ESMO Virtual Advanced Course on Clinical Questions in Prostate
ESMO 2019: Overall Survival Interim Analysis Results of the Phase 3 SPARTAN Trial
Elucidate Metastatic Prostate Cancer Targets with Radioligand Therapy and Molecular Profiling: Advancing Precision Medicine in Prostate Cancer | ESMO
Fred Saad, ESMO 2022: Phase 3 PROpel trial of abiraterone and olaparib for patients with prostate cancer - Biomarker analysis and updated results - touchONCOLOGY
Table 2 from Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Semantic Scholar
New Perspectives in the Management of Prostate Cancer | ESMO
Guidelines for genetic testing
Advanced Prostate Cancer: How Do We Move Forward in Patient Management? | ESMO
Possible changes in the standard of care for prostate cancer
